Want to see SDGR full AI Analyst Report?
EarningsQ2 2026 Earnings Report
SDGR Q2 2026 EPS Results
Actual EPS$0.08
Consensus EPS-$0.41
Beat/MissBeat by +$0.49
One Year Ago EPS-$0.59
SDGR Q2 2026 Revenue Results
Actual Revenue$58.89M
Expected Revenue$47.19M
Beat/MissBeat by +$11.70M
YoY Revenue Growth+7.54%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
SDGR Upcoming Earnings
Schrodinger's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
SDGR Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum driven by robust ACV growth, accelerating hosted adoption, the early launch and customer deployment of Bunsen, notable one-time collaboration milestones (e.g., $10M Ajax milestone) and a return to quarterly profitability with a solid cash position. Counterbalancing this optimism are near-term margin and revenue recognition pressures from the accelerated hosted licensing transition, a decline in contribution revenue tied to grant timing, and multi-quarter adoption timelines for new products like predictive toxicology. Guidance shows moderate full-year ACV growth (10%–15%), reflecting a more conservative outlook than Q2’s run-rate. Overall, positives around product innovation, customer expansion, and financial position outweigh the transitional challenges while leaving some execution and timing risks to monitor.Company Guidance
Strong ACV Growth
Total ACV of $29.6M in Q2, up 27% year over year; ACV excluding contribution $22.6M, up 23% YoY; trailing four-quarter ACV reached $208M; first half 2026 ACV of $58.0M, up 19% vs H1 2025.
Revenue and Software Momentum
Total revenue of $58.9M in Q2 with software revenue of $32.5M. Hosted software adoption accelerated: hosted revenue was $15.2M, representing 47% of software revenue (vs 31% in Q2 2025). Trailing four-quarter hosted revenue increased to 30% of software (from 23% in Q2 2025).
Profitability and Balance Sheet Strength
Net income of $6M in Q2 vs a net loss of $43M in Q2 2025. Strong liquidity position with $419M in cash and marketable securities and fully diluted share count of 75.8M.
Drug Discovery Revenue Upside
Drug discovery revenue grew to $23.0M in Q2 from $13.9M in Q2 2025, primarily driven by a $10M collaboration milestone from Ajax Therapeutics; full-year drug discovery revenue guidance raised to $65M–$75M (up from prior $55M–$65M).
Operating Discipline
Total operating expenses decreased 6% YoY to $74M in Q2, driven by lower headcount, CRO costs, and professional services fees; company expects 2026 operating expenses to be less than 2025.
Product and Commercial Expansion — Bunsen Launch
Official early-access launch of Bunsen, the agentic AI co-scientist; strategic deployment with Bristol Myers Squibb and partnerships with NVIDIA and Google Cloud to support early access. Bunsen expected to increase platform throughput and broaden user base via throughput-based licensing.
Predictive Tox and New Product Contributions
Predictive toxicology product entered commercial evaluations and has already contributed to 2026 ACV (supported by a $5M Gates Foundation extension). Other new products like retrosynth are also contributing to ACV growth and expansion into new budgets.
Therapeutics Portfolio Progress and Partnerships
New global collaboration with Simcere; since 2020 the company has realized over $750M from therapeutics activities (collaborations, co-invented drugs, co-founded companies), including value from Ajax acquisition; positive Phase 1 data for Ajax's AJ1-11095 noted.
SDGR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed